Phase 3, Randomized, Open-label, Controlled, Multiple-Dose, Efficacy, Safety, Pharmacokinetic, and Pharmacodynamic Study of Etelcalcetide in Pediatric Subjects 28 days to lesser than 18 Years of age With Secondary Hyperparathyroidism and Chronic Kidney Disease Receiving Maintenance Hemodialysis
Phase of Trial: Phase III
Latest Information Update: 13 Nov 2019
Price : $35 *
At a glance
- Drugs Etelcalcetide (Primary)
- Indications Secondary hyperparathyroidism
- Focus Registrational; Therapeutic Use
- Sponsors Amgen
- 28 May 2019 Status changed from not yet recruiting to recruiting.
- 29 Mar 2019 Planned initiation date changed from 20 Mar 2019 to 29 Apr 2019.
- 24 Oct 2018 Planned initiation date changed from 29 Dec 2018 to 20 Mar 2019.